Compare first-line EGFR-mutated lung cancer options: amivantamab combos vs osimertinib plus chemo, weighing survival, MET amplification coverage, toxicity, and visits.
Back
Clinical Management of EGFR-Mutated Advanced NSCLC
Narjust Florez, MD, highlights evolving treatment strategies and considerations for EGFR-mutated advanced non–small cell lung cancer
Clinical Management of EGFR-Mutated Advanced NSCLC
Episodes
All
All
New data show subcutaneous amivantamab matches IV efficacy, cuts infusion reactions and steroid prep, and slashes clinic time and costs.
PALOMA-3: subcutaneous amivantamab matches IV levels, slashes infusion reactions and steroids, and shortens clinic time.
New subcutaneous amivantamab cuts infusion reactions and steroid burden, reduces clinic visits, and shows improved outcomes in PALOMA-3.
High tumor burden lung cancer demands fast action: start chemo while awaiting biomarkers, then add osimertinib for rapid symptom relief.
High tumor burden lung cancer demands fast action: start chemo while awaiting biomarkers, then add osimertinib for quicker symptom relief.
Advertisement
Advertisement
Trending on OncLive
1
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
2
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
3
Mo-Rez Advances Into Combination Studies Following Robust Responses in Gynecologic Cancers
4
mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC
5